Warner-lambert Company

Stephen C Bergmeier

Haile Tecle

Walter H Moos

Lawrence D Wise

Juan C Jaen

David A Downs

David W Moreland

Anthony J Thomas

Jeffrey A Kester

Mark C Mcmills

4-(N-Substituted amino)-2-butynyl-1-carbamates and thiocarbamates and derivatives thereof are described, as well as methods for the preparation and pharmaceutical compositions of same, which are useful as centrally acting muscarinic agents and are useful as analgesic agents for the treatment of pain, as sleep aids and as agents for treating the symptoms of senile dementia, Alzheimer's disease, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, or similar conditions of cerebral insufficiency characterized by decreased cerebral acetylcholine production or release.

4-(N-substituted amino)-2-butynyl-1-carbamates and thiocarbamates and

Certain O-substituted-1,2,5,6-tetrahydro-3- or 1,2,3,6-tetrahydro-4-pyridine oximes are useful as agents for treating pain or for treating the symptoms of senile cognitive decline.

O-substituted tetrahydropyridine oxime cholinergic agents

A unique series of 4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkylpyridinyl)-2-thiazolamines are disclosed. These compounds are useful as dopaminergic agents. Intermediates for preparing the compounds, pharmaceutical compositions containing them, and methods for using the pharmaceutical compositions for treating human psychosis, elevated blood pressure, Parkinson's disease, hyperprolactinaemia, sexual disorders, and acromegaly are described.

4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and

Certain O-substituted 1-(1,2,3,6-tetrahydro-1-methyl-3-pyridinyl)ketone oximes and O-substituted 1-(1,2,3,6-tetrahydro-4-pyridinyl)ketone oximes are useful as analgesic agents or agents for the treatment or amelioration of the symptoms of cerebral insufficiency characterized by decreased central acetylcholine production or release. Pharmaceutical compositions containing the compounds and methods of using the compositions in a pharmaceutical method are also disclosed.

A unique series of 4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-pyridinyl)-2-thiazolamines are disclosed. These compounds are useful as dopaminergic agents. Intermediates for preparing the compounds, pharmaceutical compositions containing them, and methods for using the pharmaceutical compositions for treating human psychosis, elevated blood pressure, Parkinson's disease, hyperprolactinaemia, sexual disorders, and acromegaly are described.

Growing community of inventors

Ann Arbor, MI, United States of America

Stephen C Bergmeier